Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Immunologic Research
Erschienen in: Immunologic Research 1-3/2010

01.12.2010

Quiescent T cells and HIV: an unresolved relationship

verfasst von: Dimitrios N. Vatakis, Christopher C. Nixon, Jerome A. Zack

Erschienen in: Immunologic Research | Ausgabe 1-3/2010

Einloggen, um Zugang zu erhalten

Abstract

The ability of HIV to infect quiescent CD4+ T cells has been a topic of intense debate. While early studies suggested that the virus could not infect this particular T cell subset, subsequent studies using more sensitive protocols demonstrated that these cells could inefficiently support HIV infection. Additional studies showed that the kinetics of infection in quiescent cells was delayed and multiple stages of the viral life cycle were marred by inefficiencies. Despite that, proviral DNA has been found in these cells presenting them as a potential viral reservoir. Therefore, a better understanding of the relationship between HIV and quiescent T cells may lead to further advances in the field of HIV.
Literatur
1.
Cotner T, Williams JM, Christenson L, Shapiro HM, Strom TB, Strominger J. Simultaneous flow cytometric analysis of human T cell activation antigen expression and DNA content. J Exp Med. 1983;157:461–72.CrossRefPubMed
2.
Healy JI, Goodnow CC. Positive versus negative signaling by lymphocyte antigen receptors. Annu Rev Immunol. 1998;16:645–70.CrossRefPubMed
3.
Tzachanis D, Freeman GJ, Hirano N, van Puijenbroek AA, Delfs MW, Berezovskaya A, et al. Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells. Nat Immunol. 2001;2:1174–82.CrossRefPubMed
4.
Walker LS, Abbas AK. The enemy within: keeping self-reactive T cells at bay in the periphery. Nat Rev Immunol. 2002;2:11–9.CrossRefPubMed
5.
Yusuf I, Fruman DA. Regulation of quiescence in lymphocytes. Trends Immunol. 2003;24:380–6.CrossRefPubMed
6.
Tzachanis D, Lafuente EM, Li L, Boussiotis VA. Intrinsic and extrinsic regulation of T lymphocyte quiescence. Leuk Lymphoma. 2004;45:1959–67.CrossRefPubMed
7.
Kuo CT, Veselits ML, Leiden JM. LKLF: a transcriptional regulator of single-positive T cell quiescence and survival. Science. 1997;277:1986–90.CrossRefPubMed
8.
Buckley AF, Kuo CT, Leiden JM. Transcription factor LKLF is sufficient to program T cell quiescence via a c-Myc–dependent pathway. Nat Immunol. 2001;2:698–704.CrossRefPubMed
9.
Di Santo JP. Lung Krupple-like factor: a quintessential player in T cell quiescence. Nat Immunol. 2001;2:667–8.CrossRefPubMed
10.
Coffer PJ. Transcriptional regulation of lymphocyte quiescence: as cunning as a FOX. Trends Immunol. 2003;24:470–1. (Author reply 471).CrossRefPubMed
11.
Haaland RE, Yu W, Rice AP. Identification of LKLF-regulated genes in quiescent CD4 + T lymphocytes. Mol Immunol. 2005;42:627–41.CrossRefPubMed
12.
Yusuf I, Kharas MG, Chen J, Peralta RQ, Maruniak A, Sareen P, et al. KLF4 is a FOXO target gene that suppresses B cell proliferation. Int Immunol. 2008;20:671–81.CrossRefPubMed
13.
Tzachanis D, Boussiotis VA. Tob, a member of the APRO family, regulates immunological quiescence and tumor suppression. Cell Cycle. 2009;8:1019–25.PubMed
14.
Burgering BM, Kops GJ. Cell cycle and death control: long live Forkheads. Trends Biochem Sci. 2002;27:352–60.CrossRefPubMed
15.
16.
Medema RH, Kops GJ, Bos JL, Burgering BM. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature. 2000;404:782–7.CrossRefPubMed
17.
Kops GJ, Dansen TB, Polderman PE, Saarloos I, Wirtz KW, Coffer PJ, et al. Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature. 2002;419:316–21.CrossRefPubMed
18.
Schmidt M, Fernandez de Mattos S, van der Horst A, Klompmaker R, Kops GJ, Lam EW, et al. Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D. Mol Cell Biol. 2002;22:7842–52.CrossRefPubMed
19.
Fabre S, Lang V, Harriague J, Jobart A, Unterman TG, Trautmann A. Stable activation of phosphatidylinositol 3-kinase in the T cell immunological synapse stimulates Akt signaling to FoxO1 nuclear exclusion and cell growth control. J Immunol. 2005;174:4161–71.PubMed
20.
21.
Ouyang W, Beckett O, Flavell RA, Li MO. An essential role of the Forkhead-box transcription factor FOXO1 in control of T cell homeostasis and tolerance. Immunity. 2009;30:358–71.CrossRefPubMed
22.
Matsuda S, Kawamura-Tsuzuku J, Ohsugi M, Yoshida M, Emi M, Nakamura Y, et al. Tob, a novel protein that interacts with p185erbB2, is associated with anti-proliferative activity. Oncogene. 1996;12:705–13.PubMed
23.
24.
25.
Weinberg JB, Matthews TJ, Cullen BR, Malim MH. Productive human immunodeficiency virus type 1 (HIV-1) infection of nonproliferating human monocytes. J Exp Med. 1991;174:1477–82.CrossRefPubMed
26.
Lewis P, Hensel M, Emerman M. Human immunodeficiency virus infection of cells arrested in the cell cycle. EMBO J. 1992;11:3053–8.PubMed
27.
McDougal JS, Mawle A, Cort SP, Nicholson JK, Cross GD, Scheppler-Campbell JA, et al. Cellular tropism of the human retrovirus HTLV-III/LAV. I. Role of T cell activation and expression of the T4 antigen. J Immunol. 1985;135:3151–62.PubMed
28.
Zagury D, Bernard J, Leonard R, Cheynier R, Feldman M, Sarin PS, et al. Long-term cultures of HTLV-III–infected T cells: a model of cytopathology of T-cell depletion in AIDS. Science. 1986;231:850–3.CrossRefPubMed
29.
Gowda SD, Stein BS, Mohagheghpour N, Benike CJ, Engleman EG. Evidence that T cell activation is required for HIV-1 entry in CD4 + lymphocytes. J Immunol. 1989;142:773–80.PubMed
30.
Stevenson M, Stanwick TL, Dempsey MP, Lamonica CA. HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J. 1990;9:1551–60.PubMed
31.
Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, Chen IS. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell. 1990;61:213–22.CrossRefPubMed
32.
Zack JA, Haislip AM, Krogstad P, Chen IS. Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle. J Virol. 1992;66:1717–25.PubMed
33.
Spina CA, Guatelli JC, Richman DD. Establishment of a stable, inducible form of human immunodeficiency virus type 1 DNA in quiescent CD4 lymphocytes in vitro. J Virol. 1995;69:2977–88.PubMed
34.
Ramilo O, Bell KD, Uhr JW, Vitetta ES. Role of CD25 + and CD25− T cells in acute HIV infection in vitro. J Immunol. 1993;150:5202–8.PubMed
35.
Borvak J, Chou CS, Bell K, Van Dyke G, Zola H, Ramilo O, et al. Expression of CD25 defines peripheral blood mononuclear cells with productive versus latent HIV infection. J Immunol. 1995;155:3196–204.PubMed
36.
Chou CS, Ramilo O, Vitetta ES. Highly purified CD25- resting T cells cannot be infected de novo with HIV-1. Proc Natl Acad Sci USA. 1997;94:1361–5.CrossRefPubMed
37.
Tang S, Patterson B, Levy JA. Highly purified quiescent human peripheral blood CD4 + T cells are infectible by human immunodeficiency virus but do not release virus after activation. J Virol. 1995;69:5659–65.PubMed
38.
Bukrinsky MI, Stanwick TL, Dempsey MP, Stevenson M. Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science. 1991;254:423–7.CrossRefPubMed
39.
Chun TW, Finzi D, Margolick J, Chadwick K, Schwartz D, Siliciano RF. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med. 1995;1:1284–90.CrossRefPubMed
40.
Korin YD, Zack JA. Progression to the G1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells. J Virol. 1998;72:3161–8.PubMed
41.
Unutmaz D, KewalRamani VN, Marmon S, Littman DR. Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes. J Exp Med. 1999;189:1735–46.CrossRefPubMed
42.
Scripture-Adams DD, Brooks DG, Korin YD, Zack JA. Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype. J Virol. 2002;76:13077–82.CrossRefPubMed
43.
Ducrey-Rundquist O, Guyader M, Trono D. Modalities of interleukin-7-induced human immunodeficiency virus permissiveness in quiescent T lymphocytes. J Virol. 2002;76:9103–11.CrossRefPubMed
44.
Barat C, Gervais P, Tremblay MJ. Engagement of ICAM-3 provides a costimulatory signal for human immunodeficiency virus type 1 replication in both activated and quiescent CD4 + T lymphocytes: implications for virus pathogenesis. J Virol. 2004;78:6692–7.CrossRefPubMed
45.
Tardif MR, Tremblay MJ. LFA-1 is a key determinant for preferential infection of memory CD4 + T cells by human immunodeficiency virus type 1. J Virol. 2005;79:13714–24.CrossRefPubMed
46.
Thibault S, Tardif MR, Barat C, Tremblay MJ. TLR2 signaling renders quiescent naive and memory CD4 + T cells more susceptible to productive infection with X4 and R5 HIV-type 1. J Immunol. 2007;179:4357–66.PubMed
47.
Barat C, Gilbert C, Tremblay MJ. Efficient replication of human immunodeficiency virus type 1 in resting CD4 + T lymphocytes is induced by coculture with autologous dendritic cells in the absence of foreign antigens. J Virol. 2009;83:2778–82.CrossRefPubMed
48.
Oswald-Richter K, Grill SM, Leelawong M, Unutmaz D. HIV infection of primary human T cells is determined by tunable thresholds of T cell activation. Eur J Immunol. 2004;34:1705–14.CrossRefPubMed
49.
Vatakis DN, Nixon CC, Bristol G, Zack JA. Differentially stimulated CD4 + T cells display altered human immunodeficiency virus infection kinetics: implications for the efficacy of antiviral agents. J Virol. 2009;83:3374–8.CrossRefPubMed
50.
Saleh S, Solomon A, Wightman F, Xhilaga M, Cameron PU, Lewin SR. CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4 + T cells to HIV-1 infection: a novel model of HIV-1 latency. Blood. 2007;110:4161–4.CrossRefPubMed
51.
Cole SW, Korin YD, Fahey JL, Zack JA. Norepinephrine accelerates HIV replication via protein kinase A-dependent effects on cytokine production. J Immunol. 1998;161:610–6.PubMed
52.
Eckstein DA, Penn ML, Korin YD, Scripture-Adams DD, Zack JA, Kreisberg JF, et al. HIV-1 actively replicates in naive CD4(+) T cells residing within human lymphoid tissues. Immunity. 2001;15:671–82.CrossRefPubMed
53.
Korin YD, Zack JA. Nonproductive human immunodeficiency virus type 1 infection in nucleoside-treated G0 lymphocytes. J Virol. 1999;73:6526–32.PubMed
54.
Plesa G, Dai J, Baytop C, Riley JL, June CH, O’Doherty U. Addition of deoxynucleosides enhances human immunodeficiency virus type 1 integration and 2LTR formation in resting CD4 + T cells. J Virol. 2007;81:13938–42.CrossRefPubMed
55.
Ganesh L, Burstein E, Guha-Niyogi A, Louder MK, Mascola JR, Klomp LW, et al. The gene product Murr1 restricts HIV-1 replication in resting CD4 + lymphocytes. Nature. 2003;426:853–7.CrossRefPubMed
56.
Simon JH, Gaddis NC, Fouchier RA, Malim MH. Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nat Med. 1998;4:1397–400.CrossRefPubMed
57.
Simon JH, Miller DL, Fouchier RA, Soares MA, Peden KW, Malim MH. The regulation of primate immunodeficiency virus infectivity by Vif is cell species restricted: a role for Vif in determining virus host range and cross-species transmission. EMBO J. 1998;17:1259–67.CrossRefPubMed
58.
Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature. 2002;418:646–50.CrossRefPubMed
59.
Conticello SG, Harris RS, Neuberger MS. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr Biol. 2003;13:2009–13.CrossRefPubMed
60.
Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, et al. DNA deamination mediates innate immunity to retroviral infection. Cell. 2003;113:803–9.CrossRefPubMed
61.
Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature. 2003;424:99–103.CrossRefPubMed
62.
Mariani R, Chen D, Schrofelbauer B, Navarro F, Konig R, Bollman B, et al. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell. 2003;114:21–31.CrossRefPubMed
63.
Marin M, Rose KM, Kozak SL, Kabat D. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med. 2003;9:1398–403.CrossRefPubMed
64.
Sheehy AM, Gaddis NC, Malim MH. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med. 2003;9:1404–7.CrossRefPubMed
65.
Stopak K, de Noronha C, Yonemoto W, Greene WC. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell. 2003;12:591–601.CrossRefPubMed
66.
Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, et al. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science. 2003;302:1056–60.CrossRefPubMed
67.
Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature. 2003;424:94–8.CrossRefPubMed
68.
Chiu YL, Soros VB, Kreisberg JF, Stopak K, Yonemoto W, Greene WC. Cellular APOBEC3G restricts HIV-1 infection in resting CD4 + T cells. Nature. 2005;435:108–14.CrossRefPubMed
69.
Kamata M, Nagaoka Y, Chen IS. Reassessing the role of APOBEC3G in human immunodeficiency virus type 1 infection of quiescent CD4 + T-cells. PLoS Pathog. 2009;5:e1000342.CrossRefPubMed
70.
Santoni de Sio FR, Trono D. APOBEC3G-depleted resting CD4 + T cells remain refractory to HIV1 infection. PLoS ONE. 2009;4:6571.CrossRef
71.
Manganaro L, Lusic M, Gutierrez MI, Cereseto A, Del Sal G, Giacca M. Concerted action of cellular JNK and Pin1 restricts HIV-1 genome integration to activated CD4 + T lymphocytes. Nat Med. 2010;16:329–33.CrossRefPubMed
72.
Vatakis DN, Kim S, Kim N, Chow SA, Zack JA. HIV Integration efficiency and site selection in Quiescent CD4 + T cells. J Virol. 2009; doi: 10.​1128/​JVI.​00356-09.
73.
Vatakis DN, Bristol G, Wilkinson TA, Chow SA, Zack JA. Immediate activation fails to rescue efficient human immunodeficiency virus replication in quiescent CD4 + T cells. J Virol. 2007;81:3574–82.CrossRefPubMed
74.
Swiggard WJ, O’Doherty U, McGain D, Jeyakumar D, Malim MH. Long HIV type 1 reverse transcripts can accumulate stably within resting CD4 + T cells while short ones are degraded. AIDS Res Hum Retroviruses. 2004;20:285–95.CrossRefPubMed
75.
Brady T, Agosto LM, Malani N, Berry CC, O’Doherty U, Bushman F. HIV integration site distributions in resting and activated CD4 + T cells infected in culture. AIDS. 2009;23:1461–71.CrossRefPubMed
76.
Pierson TC, Zhou Y, Kieffer TL, Ruff CT, Buck C, Siliciano RF. Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection. J Virol. 2002;76:8518–31.CrossRefPubMed
77.
Zhou Y, Zhang H, Siliciano JD, Siliciano RF. Kinetics of human immunodeficiency virus type 1 decay following entry into resting CD4 + T cells. J Virol. 2005;79:2199–210.CrossRefPubMed
78.
Swiggard WJ, Baytop C, Yu JJ, Dai J, Li C, Schretzenmair R, et al. Human immunodeficiency virus type 1 can establish latent infection in resting CD4 + T cells in the absence of activating stimuli. J Virol. 2005;79:14179–88.CrossRefPubMed
79.
O’Doherty U, Swiggard WJ, Malim MH. Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J Virol. 2000;74:10074–80.CrossRefPubMed
80.
O’Doherty U, Swiggard WJ, Jeyakumar D, McGain D, Malim MH. A sensitive, quantitative assay for human immunodeficiency virus type 1 integration. J Virol. 2002;76:10942–50.CrossRefPubMed
81.
Agosto LM, Yu JJ, Dai J, Kaletsky R, Monie D, O’Doherty U. HIV-1 integrates into resting CD4 + T cells even at low inoculums as demonstrated with an improved assay for HIV-1 integration. Virology. 2007;368:60–72.CrossRefPubMed
82.
Han Y, Lassen K, Monie D, Sedaghat AR, Shimoji S, Liu X, et al. Resting CD4 + T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J Virol. 2004;78:6122–33.CrossRefPubMed
83.
Nishimura Y, Sadjadpour R, Mattapallil JJ, Igarashi T, Lee W, Buckler-White A, et al. High frequencies of resting CD4 + T cells containing integrated viral DNA are found in rhesus macaques during acute lentivirus infections. Proc Natl Acad Sci USA. 2009;106:8015–20.CrossRefPubMed
84.
Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med. 2009;15:893–900.CrossRefPubMed
85.
Auewarakul P, Wacharapornin P, Srichatrapimuk S, Chutipongtanate S, Puthavathana P. Uncoating of HIV-1 requires cellular activation. Virology. 2005;337:93–101.CrossRefPubMed
Metadaten
Titel
Quiescent T cells and HIV: an unresolved relationship
verfasst von
Dimitrios N. Vatakis
Christopher C. Nixon
Jerome A. Zack
Publikationsdatum
01.12.2010
Verlag
Humana Press Inc
Erschienen in
Immunologic Research / Ausgabe 1-3/2010
Print ISSN: 0257-277X
Elektronische ISSN: 1559-0755
DOI
https://doi.org/10.1007/s12026-010-8171-0

Weitere Artikel der Ausgabe 1-3/2010

Immunologic Research 1-3/2010 Zur Ausgabe

OriginalPaper

A challenge for the future: aging and HIV infection

OriginalPaper

Biology and pathophysiology of the new human retrovirus XMRV and its association with human disease

OriginalPaper

Signaling through the P38 and ERK pathways: a common link between HIV replication and the immune response

OriginalPaper

HIV-associated immune dysfunction and viral infection: role in the pathogenesis of AIDS-related lymphoma

OriginalPaper

The use of cell-delivered gene therapy for the treatment of HIV/AIDS

EditorialNotes

Introduction

Neu im Fachgebiet HNO

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

HNO-Op. auch mit über 90?

16.04.2024 HNO-Chirurgie Nachrichten

Mit Blick auf das Risiko für Komplikationen nach elektiven Eingriffen im HNO-Bereich scheint das Alter der Patienten kein ausschlaggebender Faktor zu sein. Entscheidend ist offenbar, wie fit die Betroffenen tatsächlich sind.

Intrakapsuläre Tonsillektomie gewinnt an Boden

16.04.2024 Tonsillektomie Nachrichten

Gegenüber der vollständigen Entfernung der Gaumenmandeln hat die intrakapsuläre Tonsillektomie einige Vorteile, wie HNO-Fachleute aus den USA hervorheben. Sie haben die aktuelle Literatur zu dem Verfahren gesichtet.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise